, Columnist
Pharma's Tax-Cut Plans Look Pretty Dull
So far the windfall looks to be headed to shareholders and balance-sheet repair.
This article is for subscribers only.
The pharma industry's reviews of corporate tax cuts are in, and -- shocker -- they're positive.
At the J.P. Morgan Healthcare Conference in San Francisco this week, executives of big, U.S.-based pharma and biotech firms spoke approvingly of new U.S. tax laws, saying they will "even the playing field" with foreign competitors, lower effective tax rates and increase financial flexibility.